Top Markets
#1 Zora Zora +42.47%
#2 AI XOVIA AI XOVIA +38.52%
#3 Full Moon Full Moon +19.13%
#4 0G 0G +18.66%
#5 Notcoin Notcoin +15.26%
#6 Axelar Axelar +14.32%
#7 Wrapped NXM Wrapped NXM +12.92%
#8 rsERG rsERG +11.77%
#9 ZKsync ZKsync +10.74%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Kexing Biopharm Co., Ltd. Kexing Biopharm Co., Ltd.

Kexing Biopharm Co., Ltd.

688136
Rank in Stocks #12397
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily... Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
Share Price
$2.99
Market Cap
$593.70M
Change (1 day)
-4.45%
Change (1 year)
-51.90%
Country
CN
Trade Kexing Biopharm Co., Ltd. (688136)

Category

Healthcare
Revenue for Kexing Biopharm Co., Ltd. (688136)
Revenue in Aug 2026 TTM: 0
According to Kexing Biopharm Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Kexing Biopharm Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH